/LGND
LGND Stock - Ligand Pharmaceuticals Incorporated
Healthcare|BiotechnologyNASDAQ
$200.33+0.97%
+$1.92 (+0.97%) • Dec 19
81
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.87
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).91
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.86
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+20.4%upside
Target: $241.20
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LGND
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$198.33 – $202.33
TARGET (TP)$241.20
STOP LOSS$184.30
RISK/REWARD1:2.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.86
52W High$212.49
52W Low$93.58
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $167.13M | $131.31M | $196.25M | $241.54M | $163.56M |
| Gross Profit | $156.06M | $96.27M | $143.42M | $179.37M | $133.14M |
| Gross Margin | 93.4% | 73.3% | 73.1% | 74.3% | 81.4% |
| Operating Income | $-22,606,000 | $11.94M | $3.04M | $103.85M | $37.50M |
| Net Income | $-4,032,000 | $52.15M | $-33,361,000 | $57.14M | $-2,985,000 |
| Net Margin | -2.4% | 39.7% | -17.0% | 23.7% | -1.8% |
| EPS | $-0.22 | $3.02 | $-1.98 | $3.46 | $-0.18 |
Company Overview
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish0 Neutral/Bearish
Price Targets
$170
Average Target
↓ 15.4% Downside
Now
$130
Low
$170
Average
$270
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Citigroup | Initiation | Buy | $270 |
| April 10th 2025 | Stifel | Initiation | Buy | $143 |
| October 3rd 2024 | Oppenheimer | Initiation | Outperform | $135 |
| July 30th 2024 | RBC Capital Mkts | Initiation | Outperform | $130 |
Earnings History & Surprises
LGNDBeat Rate
72%
Last 18 quarters
Avg Surprise
+9.1%
EPS vs Estimate
Beats / Misses
13/5
Last 12 quarters
Latest EPS
$3.09
Q4 2025
EPS Surprise History
Q1 24
+81.0%
$1.05vs$0.58
Q2 24
+6.2%
$1.20vs$1.13
Q3 24
+27.3%
$1.40vs$1.10
Q4 24
-152.0%
$-0.39vs$0.75
Q1 25
-219.7%
$-1.64vs$1.37
Q2 25
+2.3%
$1.33vs$1.30
Q3 25
+3.9%
$1.60vs$1.54
Q4 25
+56.9%
$3.09vs$1.97
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $1.46 | — | — | — |
Q4 2025 | Nov 6, 2025 | $1.97 | $3.09 | +56.9% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $1.54 | $1.60 | +3.9% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $1.30 | $1.33 | +2.3% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $1.37 | $-1.64 | -219.7% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $0.75 | $-0.39 | -152.0% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $1.10 | $1.40 | +27.3% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $1.13 | $1.20 | +6.2% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $0.58 | $1.05 | +81.0% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $0.68 | $1.02 | +50.0% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $0.76 | $1.42 | +86.8% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $0.89 | $2.28 | +156.2% | ✓ BEAT |
Q1 2023 | Feb 22, 2023 | $1.23 | $1.36 | +10.6% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $0.45 | $0.41 | -8.9% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $0.54 | $0.34 | -37.0% | ✗ MISS |
Q2 2022 | May 4, 2022 | $0.61 | $0.58 | -4.9% | ✗ MISS |
Q1 2022 | Feb 17, 2022 | $1.38 | $1.80 | +30.4% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $1.02 | $1.58 | +54.9% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $1.36 | $1.63 | +19.9% | ✓ BEAT |
Latest News
RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $235
📈 PositiveBenzinga•Dec 10, 2025, 02:26 PM
Stifel Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $230
📈 PositiveBenzinga•Dec 10, 2025, 01:04 PM•Also:
Citigroup Initiates Coverage On Ligand Pharmaceuticals with Buy Rating, Announces Price Target of $270
📈 PositiveBenzinga•Dec 9, 2025, 07:37 PM•Also:
Reported Earlier: Ligand Updates 5-Year Outlook: Long–Term Royalty Receipts Expected To Deliver At Least A 23% CAGR; Existing Commercial Programs And Late-Stage Pipeline Support Royalty Revenue CAGR Of 20%
📈 PositiveBenzinga•Dec 9, 2025, 03:56 PM
Reported Earlier: Ligand Projects 2026 Revenue Of $245M-$285M, Core Adj. EPS $8.00–$9.002
📈 PositiveBenzinga•Dec 9, 2025, 03:55 PM
Reported Earlier: Ligand Reaffirms 2025 Guidance: Sees Core Revenue $225M-$235M, Core Adj. EPS Of $7.40–$7.65
📈 PositiveBenzinga•Dec 9, 2025, 03:55 PM
Eledon Pharmaceuticals Data From First Six Participants Of Investigator-Initiated Study Of Anti-CD40 Ligand Demonstrates Marked Improvements In Glycemic Control
📈 PositiveBenzinga•Nov 18, 2025, 09:08 PM•Also:
RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $234
📈 PositiveBenzinga•Nov 10, 2025, 03:57 PM
Benchmark Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $220
📈 PositiveBenzinga•Nov 7, 2025, 03:44 PM
HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $231
📈 PositiveBenzinga•Nov 6, 2025, 06:30 PM
Ligand Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 guidance above estimates.
📈 PositiveBenzinga•Nov 6, 2025, 01:42 PM
Ligand Pharmaceuticals Raises FY2025 Adj EPS Guidance from $6.70-$7.00 to $7.40-$7.65 vs $6.87 Est; Raises FY2025 Sales Guidance from $200M-$225M to $225M-$235M vs $214.981M Est
📈 PositiveBenzinga•Nov 6, 2025, 12:10 PM
Ligand Pharmaceuticals Q3 Adj. EPS $3.09 Beats $1.92 Estimate, Sales $115.461M Beat $58.795M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 12:07 PM
Oppenheimer Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $250
📈 PositiveBenzinga•Nov 3, 2025, 03:47 PM
Ligand's Captisol Technology Powers New FDA-Approved Lasix ONYU for At-Home Edema Treatment in Heart Failure Patients
📈 PositiveBenzinga•Oct 9, 2025, 11:16 AM
Arecor And Ligand Pharmaceuticals Sign Royalty And Technology Access Deal For AT220 And AT292 Worth Up To $11M
📈 PositiveBenzinga•Sep 25, 2025, 06:54 AM
Oppenheimer Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $190
📈 PositiveBenzinga•Sep 3, 2025, 02:43 PM
Benchmark Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $175
📈 PositiveBenzinga•Sep 2, 2025, 01:44 PM
HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $206
📈 PositiveBenzinga•Aug 28, 2025, 04:34 PM
Ligand Pharmaceuticals to offer $400M convertible senior notes in private placement
➖ NeutralSeeking Alpha•Aug 11, 2025, 12:51 PM
Frequently Asked Questions about LGND
What is LGND's current stock price?
Ligand Pharmaceuticals Incorporated (LGND) is currently trading at $200.33 per share. The stock has moved +0.97% today.
What is the analyst price target for LGND?
The average analyst price target for LGND is $241.20, based on 1 analyst.
What sector is Ligand Pharmaceuticals Incorporated in?
Ligand Pharmaceuticals Incorporated operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is LGND's market cap?
Ligand Pharmaceuticals Incorporated has a market capitalization of $3.94 billion, making it a mid-cap company.
Does LGND pay dividends?
No, Ligand Pharmaceuticals Incorporated does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACAD
ACADIA Pharmaceuticals Inc.
$27.16
Mkt Cap: $4.6B
ADMA
ADMA Biologics, Inc.
$19.58
Mkt Cap: $4.7B
BLTE
Belite Bio, Inc
$156.00
Mkt Cap: $5.4B
CRNX
Crinetics Pharmaceuticals, Inc.
$48.01
Mkt Cap: $4.6B
DYN
Dyne Therapeutics, Inc.
$19.85
Mkt Cap: $2.8B
MIRM
Mirum Pharmaceuticals, Inc.
$77.74
Mkt Cap: $3.8B
NAMS
NewAmsterdam Pharma Company N.V.
$35.11
Mkt Cap: $4.0B
PRAX
Praxis Precision Medicines, Inc.
$272.92
Mkt Cap: $5.8B
SLNO
Soleno Therapeutics, Inc.
$47.85
Mkt Cap: $2.6B
VKTX
Viking Therapeutics, Inc.
$35.19
Mkt Cap: $4.0B
Explore stocks similar to LGND for comparison